Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 6;65:103242. doi: 10.1016/j.ebiom.2021.103242

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 4 — Exendin-4 reduced PSMA2 expression, cell proliferation, and tumour volume in vitro and in vivo. (a) The RNA expression of psma2 was measured in CUP-1 cells after treatment with Exendin-4 at the concentration of 0, 5, 20, and 50 nmol/L for 48 h in normal or high glucose medium. (b-d) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-shRNA-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (e-g) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-O/E-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (h) The RNA expression of psma2 was examined in SiHa, HeLa, and C33A human cervical cancer cell lines with or without Exendin-4 treatment in normal or high glucose medium. (i-j) Tumour volume was measured twice weekly after inoculation of CUP-1 cells with treatment of Exendin-4 (30 nmol/kg) or vehicle (PBS) (N = 7 in each group). Cell proliferation marker Ki67 (k-l) (red: Ki67, blue: DAPI, magnification: × 200. The white scale bar represents 50 μm) and PSMA2 expression (m-n) were measured in the tumour of above diabetes/cancer mice (red: PSMA2, blue: DAPI, magnification: × 400. The white scale bar represents 25 μm). Data are presented as mean±SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)

Fig 4 — Exendin-4 reduced PSMA2 expression, cell proliferation, and tumour volume in vitro and in vivo. (a) The RNA expression of psma2 was measured in CUP-1 cells after treatment with Exendin-4 at the concentration of 0, 5, 20, and 50 nmol/L for 48 h in normal or high glucose medium. (b-d) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-shRNA-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (e-g) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-O/E-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (h) The RNA expression of psma2 was examined in SiHa, HeLa, and C33A human cervical cancer cell lines with or without Exendin-4 treatment in normal or high glucose medium. (i-j) Tumour volume was measured twice weekly after inoculation of CUP-1 cells with treatment of Exendin-4 (30 nmol/kg) or vehicle (PBS) (N = 7 in each group). Cell proliferation marker Ki67 (k-l) (red: Ki67, blue: DAPI, magnification: × 200. The white scale bar represents 50 μm) and PSMA2 expression (m-n) were measured in the tumour of above diabetes/cancer mice (red: PSMA2, blue: DAPI, magnification: × 400. The white scale bar represents 25 μm). Data are presented as mean±SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)